S. Virabhak

发表

Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan

D. Mitchell, A. Igarashi, Scott J Johnson, 2016, Journal of medical economics.

Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection

H. Parise, Scott J Johnson, D. Misurski, 2016, Journal of medical economics.

Cost-effectiveness of treating Hepatitis C Virus (HCV) Genotype 1 (GT1) patients with abbvie 3D (Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir) +/- ribavirin compared to harvoni (Sofosbuvir/Ledipasvir) in the United States

H. Parise, S. Marx, Scott J Johnson, 2015 .

Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana.

J. Shinogle, S. Virabhak, 2005, The American journal of managed care.

Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States

H. Parise, S. Saab, Scott J Johnson, 2016, Advances in Therapy.

Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin Regimen for Patients Infected with Chronic Hepatitis C Virus Genotype 1 in Malaysia.

A. Shafie, A. A. Shafie, Y. S. Gonzalez, 2020, Value in health regional issues.

The impact of Medicaid's preferred drug lists on physicians' prescribing behaviour

Wook Sohn, S. Virabhak, 2009 .

Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States

S. Shapouri, H. Parise, M. Davids, 2020, PharmacoEconomics.

PRM29 Preliminary Validation of the Work Productivity Activity Impairment (WPAI) in Caregivers of Children Hospitalized for Respiratory Illness (WPAI: CHRI) in Germany and Canada

I. Mitchell, S. Virabhak, M. Reilly, 2012 .

Total factor productivity growth in Singapore’s service industries

S. Virabhak, Lin-Yeok Tan, 1998 .

A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan

K. Chayama, D. Mitchell, H. Kumada, 2019, Advances in Therapy.

The Singapore National Precision Medicine Strategy

Chee Yong Chua, P. Gluckman, T. Tan, 2023, Nature Genetics.

Assessing the cost-effectiveness of precision medicine: protocol for a systematic review and meta-analysis

T. Anothaisintawee, Y. Teerawattananon, S. Virabhak, 2022, BMJ Open.

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US

H. Parise, S. Saab, S. Marx, 2016, Journal of Medical Economics.

Evaluating the Value for Money of Precision Medicine from Early Cycle to Market Access: a comprehensive review of approaches and challenges.

D. Matchar, Y. Teerawattananon, S. Virabhak, 2023, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.